Cutler Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Cutler Group’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-300	Closed	-$6K	–	6645
2020 Q4	$6K	Buy	+300	New	+$26.5K	﹤0.01%	3599
2020 Q3	–	Sell	-1,100	Closed	-$2K	–	5497
2020 Q2	$2K	Sell	1,100 -7,200	-87%	-$335K	﹤0.01%	3914
2020 Q1	$35K	Buy	8,300 +6,500	+361%	+$331K	﹤0.01%	1960
2019 Q4	$7K	Buy	+1,800	New	+$89.1K	﹤0.01%	2889

Cutler Group's EIDX Position: Q1 2021 in Review

Cutler Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 170 shares — an estimated $22K sold.

Cutler Group first reported a position in EIDX in Q4 2019 and held it in 3 quarters. The position peaked at $344K in Q4 2019. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Cutler Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Cutler Group sold 170 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $22K.
Cutler Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
Cutler Group's Eidos Therapeutics, Inc. Common Stock position peaked at $344K in Q4 2019.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Cutler Group's 13F filing for Q1 2021, filed 26 Apr 2021.